Effect of Antisense Oligonucleotide to AnnexinⅡon the t-PA-mediated Plasmi nogen Activation in vitro

Annexin ,a calcium- regulated,phospho-lipid- binding protein on endothelial cells,macrophages and some tumor cells,is a cell- sur-face co- receptor for both plasminogen( PL G) andits activator,tissue plasminogen activator ( t-PA ) [1] .Annexin contains three distinct func-tional regions:N- terminal region,C- terminal re-gion,and core region.The core region of annexin contains the Ca2 +- and phospholipid- bindingsites[2 ] .The C- terminal region contains the plas-minogen- binding domain a…     

亚甲蓝治疗三叉神经痛80例

亚甲蓝治疗三叉神经痛８０例１５３医院（河南省郑州市４５００６５）陈永明，胡豫生，魏寅亮，陈桂荣我院疼痛科自１９９１年２月～１９９３年２月，用亚甲蓝阻滞治疗三叉神经痛８０例，其中男性４６例，女性３４例，年龄３１～７８岁。病程最短４天．最长６年，平均８个...     

短讯

新型医用一次性无菌敷料不久前由解放军第153医院副主任护师杨端球研制成功,并获得国家实用新型专利。该成果现已通过卫生部门的鉴定,投入生产。这种新型敷料以高级无毒绒毛浆(一种木浆)、吸水纸和非纺布为原料制成,质地柔软,对伤口无刺激,通气性好,不粘附,吸水性是普通     

Study on the Mechanism of the Annexin -Mediated Co-Assembly of t-PA and Plasminogen

Annexin ,a calcium- dependent phospholipidbinding protein with molecular weight of3 6 k D,isa member of annexin family consisting of1 3 mem-bers in mammalians.This phospholipid- bindingprotein is distinct from the urokinase receptor andfrom other known cellular binding sites for plas-minogen (PLG) and tissue plasminogen activator(t- PA) .Endothelial cells express abundant bind-ing sites for the fibrinolytic zymogen and t- PA.Binding of PLG to endothelial cells enhances thecatalytic efficie…     

VM－26治疗造血系统恶性肿瘤：18例疗效观察

ＶＭ－２６治疗造血系统恶性肿瘤：１８例疗效观察同济医科大学血液病研究所邹萍，夏凌辉，刘新月，吴裕丹，胡俊斌，张义成，胡豫，彭孝廉，宋善俊鬼臼噻吩甙（Ｔｅｎｉｐｏｓｉｄｅ，简称ＶＭ－２６）商品名威猛（Ｖｕｍｏｎ）．是一种鬼臼毒素的衍生物，具有强烈的抗肿...     

军队医院专利工作的特点及发展方向

专利是科学技术的成果和结晶，其数质量是衡量一个国家、一个系统科技经济实力和竞争力的显标志，为了对我军医院专利工作的现状及未来发展有一个基本认识，我们调查了1985年9月～1997年12月间军队医院专利申请的数量和内容，并就此展开了对军队医院专利工作特点和今后发展方向的探讨。     

表达脑源性神经营养因子的人多发性骨髓瘤小鼠模型的建立

过去的研究证实脑源性神经营养因子(BDNF)在体外具有促进多发性骨髓瘤(MM)细胞增殖并诱导MM血管新生的能力。本研究探讨BDNF/TrkB途径是否为治疗MM的潜在靶点,并比较两种途径建立人MMNOD/SCID小鼠模型的优缺点,为深入探索治疗MM的新靶点奠定基础。选择糖尿病抵抗/重症联合免疫缺陷(NOD/SCID)小鼠,通过皮下注射或尾静脉注射人骨髓瘤细胞株RPMI8226建立两种异体移植动物模型。观察荷瘤后小鼠的生长状态,测量皮下瘤块的体积;荷瘤后3周,每周经眼眶后静脉丛采血,检测血清中人源λ轻链含量、Ca2 浓度和血浆中人源BDNF浓度,并计数红细胞;小鼠死后,采用组织学方法观察瘤细胞的形态特征,流式细胞术检测小鼠外周血和骨髓中人源性CD38 细胞比例,采用计算机X线数字摄影观察小鼠全身骨密度的改变和骨质破坏情况。结果表明:皮下注射模型的成瘤率高(5/5),具有多种与浆细胞瘤相似的病理学特征,但其骨髓中未检测到MM细胞,血清中钙离子浓度不高,M蛋白浓度升高不明显且未发现溶骨性损害的组织学和影像学证据。尾静脉注射模型成瘤率相对较低(4/7),骨髓中可检测到呈浸润生长的人CD38 细胞;而且在荷瘤3周后,血清中即可检测到人源M蛋白;随着肿瘤的生长,M蛋白水平、钙离子浓度逐渐升高,并有溶骨性损害的影像学证据。两种模型血浆中人源BDNF的水平亦逐渐升高,9周时浓度分别为(73±11)pg/ml和(105±18)pg/ml。结论:本研究成功建立了两种高表达BDNF的MM荷瘤NOD/SCID小鼠模型,两种模型相互结合应用,为探索MM治疗的新靶点BDNF/TrkB提供了合适的动物模型。     

新型口服抗凝剂在肿瘤相关静脉血栓栓塞症治疗中的应用

<正>恶性肿瘤是静脉血栓形成的重要危险因素,大约有5%～20%的恶性肿瘤患者会发生静脉血栓栓塞症(venous thromboembolism,VTE)。同时,VTE是患者除外恶性肿瘤进展或复发之外的首要死亡原因[1]。相较于非肿瘤患者来说,恶性肿瘤本身可使VTE风险增加4～6倍。此外,肿瘤化疗、某些靶向治疗、激素治疗或放疗以及中心静脉导管置管都进一步增加了VTE风险[2]。与未发生VTE的恶性肿瘤患者相比,VTE患者的生存率更低,预后更差,医疗费用更高。尽管危害重大,恶性     

Once- versus twice-weekly Bortezomib induction therapy with dexamethasone in newly diagnosed multiple myeloma

In this study,we administered a modified schedule of weekly intravenous Bortezomib at 1.6 mg/m 2 with dexamethasone(BD) and compared it to the standard 1.3 mg/m 2 twice-weekly BD regimen in Chinese patients with newly diagnosed multiple myeloma(MM).We assessed the difference in efficacy,safety profile and survival between the once-weekly and twice-weekly cohorts(13 vs.24 patients).The over response rate was similar with both arms of the study,being 77% in the once-weekly schedule and 74.9% in the twice-weekly schedule(P=0.690).The median overall survival was not reached in either schedule.Also,the median progression-free survival and duration of response of the once-weekly schedule did not significantly differ from those of the twice-weekly schedule(8 months vs.10 months,P=0.545 and 6 months vs.7 months,P=0.467 respectively).Peripheral sensory neuropathy and grade 3/4 hematologic toxic effects were more frequently reported in the twice-weekly schedule than the once-weekly schedule,but there was no statistically significant difference.This preliminary experience in Chinese patients with newly diagnosed MM indicated that once-weekly infusion of Bortezomib plus dexamethasone may improve safety without affecting outcome.